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he International Diabetes Federa-
tion (IDF) recently published
guidelines for the management of
postmeal hyperglycemia. These guide-
lines were established in view of the risk
of postmeal hyperglycemia for vascular




cusing on the detection and therapy of
postprandialhyperglycemia.Besidesnon-
pharmacological measures (blood glucose
self-control and diet), drugs such as short-
acting insulinotropic agents (sulfonylureas
and glinides), glucosidase inhibitors, insu-
lin, and incretin-based therapies can specif-
ically be used to act on postmeal glucose
elevations. The speciﬁc action proﬁles of
these agents are shown and discussed with
respect to the IDF guidelines.
POSTMEAL
HYPERGLYCEMIA AS A
RISK FACTOR IN TYPE 2
DIABETES— Type 2 diabetes is a
chronic and progressive disease that af-
fects 250 million people worldwide to-
day, with an increasing incidence in the
years to come (1). With this epidemic di-
mension, type 2 diabetes is of global con-
cern. Poor control of the disease is a
leading cause of death in most developed
countriesandisassociatedwithmicrovas-




complications such as diabetic neuropa-
thy. Macrovascular complications are the
major cause of death in type 2 diabetic
patients (2–7).
Numerous epidemiological studies
have shown that postprandial hyperglyce-
mia substantially adds to the micro- and
macrovascular risk not only in type 1 and
type2diabetes,butalreadyinimpairedglu-
cose tolerance (2–4,8). The associations
between postmeal hyperglycemia and
markers of cardiovascular disease such as
oxidative stress, inﬂammation, endothe-
lial dysfunction, and carotid IMT have
been well characterized. In addition,
postprandialhyperglycemiahasalsobeen
connected with the incidence of carcino-
mas and cognitive dysfunction in elderly
type 2 diabetic patients (9–11).
Large intervention trials showed that
antihyperglycemic therapy with treat-
ment goals aiming at normoglycemia can
signiﬁcantly reduce the risk or the pro-
gression for the above-mentioned vascu-
lar risk (11–16). However, normalizing
A1C alone is not sufﬁcient in risk reduc-
tion. A distinct glycemic threshold for the
reduction of complications has not been
found; therefore, the goal of antidiabetic
treatment should be to achieve near-
normoglycemia as safely as possible re-
garding A1C, fasting plasma glucose, and
postprandial glucose concentrations. Be-
cause normal A1C levels cannot be
reachedbytreatingfastingplasmaglucose
alone, postprandial glucose also has to be
considered in therapeutic strategies.
Therefore, treatment of fasting and post-
meal hyperglycemia should be initiated
simultaneously at any A1C level. Espe-
cially at lower A1C concentrations, the
proportionalcontributionofpostprandial
glucose to A1C is greater than at higher
A1C values (17). In addition, a prospec-
tive intervention study in a cohort with
impaired glucose tolerance demonstrated
that by reducing postmeal glucose with a
pharmacological intervention by using an
-glucosidase inhibitor, macrovascular
events could be reduced signiﬁcantly (9).
OBJECTIVE OF THE IDF
GUIDELINES FOR THE
MANAGEMENT OF
POSTMEAL GLUCOSE— The ob-
jective of the IDF guidelines for the man-
agement of postmeal glucose was to
present data on the exact relationship of
postmealhyperglycemiaandthedevelop-
mentofdiabeticcomplications.Fromthis
evidence, recommendations have been
developed and stated in the guidelines to
aidclinicianstoeffectivelytreatpostpran-
dial hyperglycemia in type 1 and type 2
diabetes.
Contents of the guidelines
Theguidelinesweredevelopedevaluating
and weighing the available literature and
expert knowledge with established meth-
ods of evidence-based medicine with re-
spect to speciﬁc questions concerning the
treatment of postmeal glucose. The spe-
ciﬁc questions raised and their recom-
mendations were as follows.
Is postmeal hyperglycemia harmful?
Postmeal hyperglycemia is harmful and
should be addressed.
Is treatment of postmeal hyperglyce-
mia beneﬁcial? Implement treatment
strategies to lower postmeal plasma glucose
in people with postmeal hyperglycemia.
Which therapies are effective in con-
trolling postmeal plasma glucose? A
variety of both nonpharmacologic and
pharmacologic therapies should be con-
sidered to target postmeal plasma
glucose.
●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●●
From the Department of Medicine IV, Eberhard-Karls-University Tu ¨bingen, Tu ¨bingen, Germany.
Corresponding author: Baptist Gallwitz, baptist.gallwitz@med.uni-tuebingen.de.
The publication of this supplement was made possible in part by unrestricted educational grants from Eli
Lilly,EthiconEndo-Surgery,GenerexBiotechnology,Hoffmann-LaRoche,Johnson&Johnson,LifeScan,
Medtronic, MSD, Novo Nordisk, Pﬁzer, sanoﬁ-aventis, and WorldWIDE.
DOI: 10.2337/dc09-S331
© 2009 by the American Diabetes Association. Readers may use this article as long as the work is properly
cited, the use is educational and not for proﬁt, and the work is not altered. See http://creativecommons.
org/licenses/by-nc-nd/3.0/ for details.
DIABETES AND CARDIOVASCULAR DISEASE
S322 DIABETES CARE, VOLUME 32, SUPPLEMENT 2, NOVEMBER 2009 care.diabetesjournals.orgWhat are the targets for postmeal gly-
cemic control and how should they be
assessed? 1)Two-hourpostmealplasma
glucose should not exceed 7.8 mmol/l
(140 mg/dl) as long as hypoglycemia is
avoided. 2) Self-monitoring of blood glu-
cose should be considered because it is
currently the most practical method for
monitoring postmeal glycemia. 3)E f ﬁ -
cacy of treatment regimens should be
monitored as frequently as needed to
guide therapy toward achieving postmeal
plasma glucose target.
The guideline contains a conclusion
that the glycemic goals stated in Table 1
should be reached, unless there are other
concerns (mainly safety regarding hypo-




Type 2 diabetes is a chronic condition
where metabolic control and therapy are
to a large extent patient driven. For this
reason, the majority of treatment guide-
lineshaveimplementedpatienteducation
and lifestyle intervention as an important
ﬁrststeptoimprovethemetabolicparam-
eters and risk factors. Patients should be
taught to change to a healthier lifestyle
with increased physical activity and to
change to a diet with an appropriate ca-
loric intake with a reduction in fat and re-
ﬁned carbohydrates. Patients should be
instructed, supported, and motivated to
make the necessary changes to successfully
implement an appropriate lifestyle
intervention.
Theglycemicindex(GI)describesthe
postmeal incremental area under the
plasma glucose curve of carbohydrates in
individual foods. Most modern starchy
foods have a relatively high GI. Foods
with a lower GI (vegetables, most fruit,
whole grains) contain starches and sugars
that are more slowly digested and ab-
sorbed. In a meta-analysis, diets with a
lowerGIwereassociatedwithmodestim-
provements in A1C. Furthermore, glyce-
mic load has been identiﬁed as an
independentriskfactorformyocardialin-
farction. In summary, the GI has a posi-
tive effect on postmeal glucose and
cardiovascular risk factors (18).
Furthermore, the patient should
know his or her therapeutic goals for gly-
cemic parameters and how to monitor
them according to the disease state and to
the treatment strategy. Self-monitoring of
blood glucose allows patients with type 2
diabetes to obtain actual concentrations
of their blood glucose with sufﬁcient
accuracy. By measuring fasting and post-
meal glucose, patients have good feedback
on their glucose excursions and can make
therapeutic decisions based on those
measurement results. The frequency of
testingdependsonthekindoftherapy;in
treatment with an intrinsic hypoglycemia
risk such as insulin therapy or treatment
withsulfonylureasandglinides,morefre-
quent measurements should be recom-
mended, and measurements should also
be performed when hypoglycemic symp-
toms occur (19).
Treatment with agents that lower
postprandial hyperglycemia
Considering pharmacological treatment,
besides an initial therapy with metformin
that is suggested as ﬁrst-line therapy in
type 2 diabetes for all patients that have
no contraindications to this drug, there is
a variety of agents that by their mode of
action act on postmeal hyperglycemia.
The choice of drugs should always take
the efﬁcacy for the patient, safety, and
cost-beneﬁt aspects into account.
SULFONYLUREAS AND
GLINIDES— These agents stimulate
insulin secretion in a glucose-indepen-
dent manner by closing the potassium/
ATP channel on the -cells. This action
leads to a depolarization of the -cells
withaconsecutiveriseinintracellularcal-
ciumthattriggersinsulinrelease.Glinides
(repaglinide and nateglinide) have a
much shorter action of only a few hours
compared with sulfonylureas because of
their pharmacokinetic properties. When
given at mealtimes with the beginning of
the meal, postprandial glucose is lowered
effectively. The occurrence of hypoglyce-
mia is associated with the glinides, but
some studies report a lower incidence of
hypoglycemia compared with sulfonyl-
urea therapy (20). When choosing a sul-
fonylurea, the action time should be
considered. In patients with renal impair-
ment, sulfonylureas may show a longer
duration of action, whereas the pharma-
cokinetics of glinides is not affected.
Sulfonylureas and glinides are effec-
tive in stages of type 2 diabetes when
-cell mass is still sufﬁcient to secrete ap-
propriate amounts of insulin. From clini-
calstudies,itisknownthatthefailurerate
to sulfonylurea therapy amounts to at
least 5–10% per year (4).
-Glucosidase inhibitors
-Glucosidase inhibitors competitively
inhibit the intestinal enzyme catalyzing
the degradation of disaccharides into
monosaccharides that are ﬁnally ab-
sorbed from the small intestine. In this
respect, -glucosidase inhibitors speciﬁ-
cally act on the slowing of carbohydrate
absorption after a meal and speciﬁcally
lower postprandial glucose. Because of
their unique mechanism of action, they
can be given at any stage of type 2 diabe-
tes, either as monotherapy (where they
have even shown a reduction in the pro-
gressionfromthepre-diabeticstateofim-
paired glucose tolerance to type 2
diabetes) or in combination with other
agents (9,21,22).
Insulin therapy
Short-acting insulins speciﬁcally address
postprandial hyperglycemia when given
in a meal-adapted manner. Regular hu-
man insulin has a maximal action 2h
after injection and a duration of action of
4 h, depending on the dose injected.
The fast-acting insulin analogs were de-
veloped to mimic the physiological insu-
lin response after a meal with a better
action proﬁle than regular human insulin
and can also be used for prandial insulin
therapy (23).
Biphasic premixed insulins contain a
certain proportion of fast-acting insulin
(either regular human insulin or a fast-
acting analog) together with an interme-
diate-actinginsulinandcanalsolowerthe
postprandial glucose excursions of the
meals, especially those that are ingested
after the insulin injection (24–27).
INCRETIN-BASED
THERAPIES
Dipeptidyl peptidase IV inhibitors
Dipeptidyl peptidase IV (DPP-4) inhibi-
tors inhibit the enzyme dipeptidyl-
peptidase IV, which cleaves and
inactivates the incretin hormones gluca-
Table 1—Glycemic goals for clinical man-
agement of diabetes according to the IDF






(fasting) 5.5 mmol/l (100 mg/dl)
2-h postmeal 7.8 mmol/l (140 mg/dl)
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hibitory polypeptide (GIP). These
hormones are physiologically secreted by
endocrine cells in the intestine postpran-
dially and stimulate insulin secretion in a
glucose-dependent manner after a meal.
They contribute to 70% of the post-
prandial insulin secretion. The biological
half-life of both hormones amounts to
only a few minutes after a meal due to
DPP-4 action. Besides stimulating insulin
secretion under hyperglycemic condi-
tions, GLP-1 also suppresses glucagon se-
cretion and thereby lowers glucose by
inhibiting hepatic glucose output. It fur-
ther slows gastric emptying and increases
satiety. DPP-4 inhibitors raise endoge-
nousGLP-1(andGIP)concentrations,re-
sulting in a signiﬁcant improvement of
glycemic parameters by enhancing the
above-described actions of GLP-1 includ-
ing normalized postprandial glucose.
DPP-4 inhibitors are effective in early
stages of type 2 diabetes, either as mono-
therapy or in combination with met-
formin or other oral monotherapies for
type 2 diabetes. They are weight neutral
and have no intrinsic risk for hypoglyce-
mic episodes. The DPP-4 inhibitors have
few known side effects; nasopharyngitis
and skin reactions are side effects that oc-
cur with a low incidence (28,29). Cur-
rently, sitagliptin is approved in many
countries and vildagliptin has just re-
ceived approval from the European Med-
icines Agency (EMEA). Further DPP-4
inhibitors are in development.
GLP-1 receptor agonists
GLP-1 receptor agonists are peptides that
use GLP-1 action and can be used as an
injectabletherapyintype2diabetes.Pres-
ently, exenatide is the only GLP-1 recep-
tor agonist approved. It is a synthetic
version of the naturally occurring peptide
exendin-4 that has a high amino acid se-
quence similarity to native GLP-1, but is
DPP-4 resistant. In comparison to DPP-4
inhibitors, weight loss is observed in pa-
tientstreatedwithexenatideandamounts
to 3–5 kg in clinical studies. Exenatide
has been shown to be equally effective in
lowering A1C in patients failing oral ther-
apy(withmetforminand/orsulfonylurea)
as insulin. In contrast to insulin therapy,
thereductionofpostprandialglucosewas
superior with exenatide compared with
insulin glargine. For this reason, ex-
enatide can be advantageous for patients
where hypoglycemic episodes have to be
avoidedandanincreaseinbodyweightas
observed with insulin therapy is not de-
sirable. The main adverse effect of ex-
enatide is nausea, which affects 40% of
patients at the beginning of therapy but is
mild to moderate and transient. Antibod-
ies are observed in 30% of patients
treated, but these are not cross-reacting
with endogenous GLP-1 and are not neu-
tralizing (28,30). Liraglutide, a human
GLP-1analog,isinphaseIIIclinicaltrials.
Besides, a long-acting release form of ex-
enatide (exenatide LAR) is also in clinical
testing as well as other GLP-1 receptor





DO WE KNOW, WHAT DO
WE NEED?— All the drugs discussed
abovehaveshowntheirefﬁcacyinlowering
postmealglucose.Dietaryinterventionisal-
ways (independently from the disease state
and duration of diabetes) a fundamental
cornerstone in the therapeutic strategy ad-
dressing postmeal hyperglycemia.
Acarbose speciﬁcally acts on post-
meal hyperglycemia and has lowered car-
diovascular events in a prospective
randomized double-blind clinical trial in
subjects with impaired glucose tolerance.
In type 2 diabetic patients, a meta-
analysis also showed a reduction of car-
diovasculareventsinpatientstreatedwith
acarbose. However, gastrointestinal side
effects and costs are a barrier to a broad
use of this compound (9,22).
Presently, many epidemiological
studies show an association of postmeal
(or postchallenge) hyperglycemia and
cardiovascular risk. However, data on the
beneﬁcial effect of a pharmacological in-
tervention on cardiovascular end points
are scarce and still missing for the just
recently released compounds (DPP-4 in-
hibitors, GLP-1 receptor agonists).
An intensiﬁed insulin therapy in type
2diabetessigniﬁcantlyreducesmicrovas-
cularcomplications.Thereductionofma-
crovascular risk, however, has not clearly
been established.
In recent long-term trials addressing
glycemic goals for the treatment of type 2
diabetes, a lowering of A1C to levels not
below 6.5% leads to a signiﬁcant reduc-
tion in microvascular end points, but ma-
crovascular end points were not reduced
signiﬁcantly. A vigorous reduction of the
A1C below levels of 6.5% lowered nonfa-
tal cardiovascular events but increased
mortalityforreasonsthatarenotfullyun-
derstood.Inthisintensivelytreatedgroup
of patients, the majority of participants
with a baseline A1C 8.0% received a
antidiabeticcombinationtherapyofmore
than two drugs and gained signiﬁcantly
more weight than the patient group hav-
ing a higher A1C goal (31,32). In this re-
spect, a safe antihyperglycemic treatment
not leading to hypoglycemia and weight
gain may be favorable, especially in pa-
tients with A1C values in the range below
7.5%, where postprandial hyperglycemia
contributes to a higher degree to the A1C
reduction.
In general, however, we will need in-
tervention studies to investigate the effect
of postmeal hyperglycemia and its treat-
ment on outcomes. These studies will
have to be large and will need to have a
long duration to clarify the open ques-
tions that still remain.
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